TrustTSC 3002 (1042-TSC-3002)
Project Description:
Title: TrustTSC 3002 (1042-TSC-3002): A phase 3 open-label safety study for subjects having Tuberous Sclerosis Complex (TSC)-related epilepsy previously treated Ganaxolone (GNX)
Role: Site PI
Funding: Marinus Pharmaceuticals
2022-present
Summary: This is an open-label expanded access program to combine subjects from previous studies receiving Ganaxolone to allow for continued treatment.
Core Function(s):
Training Trainees, Continuing Education/Community Training
Area of Emphasis
Education & Early Intervention, Child Care-Related Activities, Other
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Other
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A